Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Rapport Therapeutics, Inc. (RAPP) had Consolidated Net Income/Loss of $-111.48M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-111.48M |
|
-- |
|
-- |
|
$125.10M |
|
$-125.10M |
|
$13.62M |
|
$-111.48M |
|
$-111.48M |
|
$-111.48M |
|
$-111.48M |
|
|
Consolidated Net Income/Loss |
$-111.48M |
$-111.48M |
|
$-125.10M |
|
$-125.48M |
|
38.94M |
|
38.94M |
|
$-2.86 |
|
$-2.86 |
|
| Balance Sheet Financials | |
$498.56M |
|
$2.98M |
|
$13.87M |
|
$512.43M |
|
$19.05M |
|
-- |
|
$8.73M |
|
$27.78M |
|
$484.65M |
|
$484.65M |
|
$484.65M |
|
47.77M |
|
| Cash Flow Statement Financials | |
$-87.47M |
|
$-187.47M |
|
$270.79M |
|
$56.91M |
|
$52.75M |
|
$-4.16M |
|
$18.86M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
26.17 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-88.09M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-23.00% |
|
-23.00% |
|
-21.76% |
|
-23.00% |
|
$10.14 |
|
$-2.26 |
|
$-2.25 |
|